trending Market Intelligence /marketintelligence/en/news-insights/trending/MXlAtyOhCLuMHkyMeXi6rQ2 content esgSubNav
In This List

Aytu BioScience launches $10M private placement


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Aytu BioScience launches $10M private placement

Aytu BioScience Inc. is raising $10 million in a private placement of its series F convertible preferred stock and warrants to buy common stock.

Institutional investors Altium Capital and Armistice Capital jointly participated in the deal.

The shares of preferred stock will be sold at $1,000 per share and are convertible into 1,000 common shares at $1 per share. The preferred shares are also accompanied by warrants to buy up to one common share for each share of common stock convertible from the preferred stock, exercisable at $1.25 per share.

The five-year warrants are exercisable following shareholder approval.

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.

Englewood, Colo.-based Aytu Bioscience develops products for hypogonadism, insomnia and male infertility. The company recently agreed to acquire a portfolio of six prescription products from Cerecor Inc. for an up-front payment of $17 million.